VivoSeq
Nephrology

Chronic Kidney Disease

451

Pipeline Programs↗

125

Active Trials↗

131

Companies Involved↗

Chronic Kidney Disease is a highly competitive landscape with 451 programs across 131 companies. The most active players are Renibus Therapeutics, Inc., La Jolla Pharmaceutical Company, Concert Pharmaceuticals. 118 therapies are approved with 99 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

93/100

Pipeline Velocity

65/100

Mech. Concentration

4/100

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Renibus Therapeutics, Inc.

3 programs

Phase 1L

La Jolla Pharmaceutical Company

1 program

Phase 1C

Concert Pharmaceuticals

1 program

Phase 1T

Taisho Pharmaceutical Co., Ltd.

1 program

Phase 1S

Salix

1 program

Phase 1K

Kind Pharmaceuticals LLC

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical68

Lorazepam

Bausch Health Americas, Inc.

Nitroglycerin

Viatris Specialty LLC

Montelukast

Organon and Co

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Alteplase

Roche

Phase 143

Rifaximin

Salix

Belatacept

Bristol-Myers Squibb

Glutamine

Sanofi

Belzutifan

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Mycophenolic Acid

Novartis

Phase 2123

Dulaglutide

Eli Lilly

Tirzepatide

Eli Lilly

Basiliximab

Novartis

Nifedipine

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Calcium Carbonate

Otsuka

Phase 399

Semaglutide

Novo Nordisk

Curcumin

Merck & Co.

Mycophenolate Sodium

Novartis

Ferrous Sulfate

Auerbach Hematology Oncology Associates P C

Metformin Hydrochloride

Boehringer Ingelheim

Approved118

Dapagliflozin

AstraZeneca

Baricitinib

Eli Lilly

Clopidogrel

Sanofi

Cinacalcet

Amgen

Propofol

Fresenius Kabi Oncology Ltd.

Analysis

Modality Breakdown

92%

Small molecule

458 of 500 classified programs — the dominant modality here.

8%ALL OTHERSPeptide112%Monoclonal antibody82%Protein / enzyme82%Vaccine82%Cell therapy71%

Small molecule leads; the ring shows all 500 classified programs, each share of the total. Modality classified for 99% of 541 pipeline programs.

Analysis

Trial Status

691

clinical trials

Completed408 · 59%
Recruiting74 · 11%
Unknown status62 · 9%
Terminated60 · 9%
Withdrawn31 · 4%
Not yet recruiting30 · 4%
Other26 · 4%

Clinical Trials

Trial Activity

691 trials

Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease
Recruiting·—·Phase 4·NCT06727409·82 enrolled
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Recruiting·AAMAG Pharmaceuticals, Inc.·Phase 3·NCT03619850·129 enrolled
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
Recruiting·UUniversity Hospital, Tours·Phase 3·NCT05732727·720 enrolled
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Recruiting·NNorthwestern University·Phase 1/2·NCT05719714·60 enrolled
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
Recruiting·Regeneron logoRegeneron·Phase 1/2·NCT05092347·56 enrolled
A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy with AION-301 Administered by Intravenous Infusion Compared with Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age with Chronic Kidney Disease (CKD)
Recruiting·AAION Healthspan, Inc.·Phase 1/2·NCT06721143·36 enrolled
Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
Recruiting·MMansoura University·Phase 2·NCT06897605·80 enrolled
Role of Vitamin K2 in Chronic Kidney Disease
Recruiting·TTanta University·Phase 4·NCT05942053·44 enrolled
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 2·NCT06717698·465 enrolled
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
Recruiting·TThe George Institute·Phase 3·NCT06058585·1,000 enrolled
Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
Recruiting·—·Phase 4·NCT04522622·48 enrolled
Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients
Recruiting·SSindh Institute of Urology and Transplantation·N/A·NCT06994065·128 enrolled
SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
Recruiting·TThe University of Hong Kong·Phase 2·NCT06155604·150 enrolled
Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in Advanced Chronic Kidney Disease
Recruiting·YYonsei University·N/A·NCT06322056·642 enrolled
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
Recruiting·TThe University of Texas Medical Branch, Galveston·Phase 4·NCT07203287·490 enrolled
Page 1 of 47

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)